Quidel
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
QuidelOrtho Withdraws Submitted Savanna Respiratory Panel, Obtains FDA Clearance for COVID-19 Test
The firm said the final performance data for the Savanna RVP4+ panel did not meet its expectations, and it will now resubmit a next-gen version.
QuidelOrtho Gets Health Canada Approval for Triage Preeclampsia Test
The approval is for an assay to detect biomarkers that may indicate the likelihood of developing preeclampsia during a pregnancy.
The firm discussed further reducing its headcount as well as increasing its molecular and lab instrument menu as a path to margin restoration.
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
Feb 21, 2024
QuidelOrtho Parts Ways With Longtime CEO Doug Bryant
Jan 16, 2024
Aug 9, 2023
QuidelOrtho Revenues up 8 Percent in Q2
Oct 12, 2022
QuidelOrtho Reports Preliminary Q3 Revenues
Sep 7, 2022
Aug 18, 2022
QuidelOrtho Board Authorizes $300M Share Repurchase
Aug 5, 2022